These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

475 related items for PubMed ID: 31072216

  • 1. Structure-based design generated novel hydroxamic acid based preferential HDAC6 lead inhibitor with on-target cytotoxic activity against primary choroid plexus carcinoma.
    Kassab SE, Mowafy S, Alserw AM, Seliem JA, El-Naggar SM, Omar NN, Awad MM.
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1062-1077. PubMed ID: 31072216
    [Abstract] [Full Text] [Related]

  • 2. Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors.
    Jiang BE, Hu J, Liu H, Liu Z, Wen Y, Liu M, Zhang HK, Pang X, Yu LF.
    Eur J Med Chem; 2022 Jan 05; 227():113893. PubMed ID: 34656899
    [Abstract] [Full Text] [Related]

  • 3. Design, Synthesis and Biological Evaluation of a Phenyl Butyric Acid Derivative, N-(4-chlorophenyl)-4-phenylbutanamide: A HDAC6 Inhibitor with Anti-proliferative Activity on Cervix Cancer and Leukemia Cells.
    Rodríguez-Fonseca RA, Sixto-López Y, Fragoso-Vázquez MJ, Flores-Mejía R, Cabrera-Pérez LC, Vázquez-Moctezuma I, Rosales-Hernández MC, Bello M, Martínez-Archundia M, Trujillo-Ferrara JG, Becerra-Martínez E, Correa-Basurto J.
    Anticancer Agents Med Chem; 2017 Jan 05; 17(10):1441-1454. PubMed ID: 28044941
    [Abstract] [Full Text] [Related]

  • 4. Design, synthesis and biological evaluation of novel hydroxamic acid based histone deacetylase 6 selective inhibitors bearing phenylpyrazol scaffold as surface recognition motif.
    Yang J, Cheng G, Xu Q, Luan S, Wang S, Liu D, Zhao L.
    Bioorg Med Chem; 2018 May 01; 26(8):1418-1425. PubMed ID: 29500130
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Combined Ligand and Fragment-based Drug Design of Selective Histone Deacetylase - 6 Inhibitors.
    Ruzic D, Petkovic M, Agbaba D, Ganesan A, Nikolic K.
    Mol Inform; 2019 May 01; 38(5):e1800083. PubMed ID: 30632697
    [Abstract] [Full Text] [Related]

  • 13. Novel 2, 5-diketopiperazine derivatives as potent selective histone deacetylase 6 inhibitors: Rational design, synthesis and antiproliferative activity.
    Chen X, Chen X, Steimbach RR, Wu T, Li H, Dan W, Shi P, Cao C, Li D, Miller AK, Qiu Z, Gao J, Zhu Y.
    Eur J Med Chem; 2020 Feb 01; 187():111950. PubMed ID: 31865013
    [Abstract] [Full Text] [Related]

  • 14. 1-Aroylindoline-hydroxamic acids as anticancer agents, inhibitors of HSP90 and HDAC.
    Ojha R, Huang HL, HuangFu WC, Wu YW, Nepali K, Lai MJ, Su CJ, Sung TY, Chen YL, Pan SL, Liou JP.
    Eur J Med Chem; 2018 Apr 25; 150():667-677. PubMed ID: 29567459
    [Abstract] [Full Text] [Related]

  • 15. PTG-0861: A novel HDAC6-selective inhibitor as a therapeutic strategy in acute myeloid leukaemia.
    Gawel JM, Shouksmith AE, Raouf YS, Nawar N, Toutah K, Bukhari S, Manaswiyoungkul P, Olaoye OO, Israelian J, Radu TB, Cabral AD, Sina D, Sedighi A, de Araujo ED, Gunning PT.
    Eur J Med Chem; 2020 Sep 01; 201():112411. PubMed ID: 32615502
    [Abstract] [Full Text] [Related]

  • 16. Oxa Analogues of Nexturastat A Demonstrate Improved HDAC6 Selectivity and Superior Antileukaemia Activity.
    Pflieger M, Sönnichsen M, Horstick-Muche N, Yang J, Schliehe-Diecks J, Schöler A, Borkhardt A, Hamacher A, Kassack MU, Hansen FK, Bhatia S, Kurz T.
    ChemMedChem; 2021 Jun 07; 16(11):1798-1803. PubMed ID: 33629513
    [Abstract] [Full Text] [Related]

  • 17. Design, synthesis and anticancer potential of NSC-319745 hydroxamic acid derivatives as DNMT and HDAC inhibitors.
    Yuan Z, Sun Q, Li D, Miao S, Chen S, Song L, Gao C, Chen Y, Tan C, Jiang Y.
    Eur J Med Chem; 2017 Jul 07; 134():281-292. PubMed ID: 28419930
    [Abstract] [Full Text] [Related]

  • 18. Design and Synthesis of Dihydroxamic Acids as HDAC6/8/10 Inhibitors.
    Morgen M, Steimbach RR, Géraldy M, Hellweg L, Sehr P, Ridinger J, Witt O, Oehme I, Herbst-Gervasoni CJ, Osko JD, Porter NJ, Christianson DW, Gunkel N, Miller AK.
    ChemMedChem; 2020 Jul 03; 15(13):1163-1174. PubMed ID: 32348628
    [Abstract] [Full Text] [Related]

  • 19. Pragmatic recruitment of memantine as the capping group for the design of HDAC inhibitors: A preliminary attempt to unravel the enigma of glioblastoma.
    Nepali K, Hsu TI, Hsieh CM, Lo WL, Lai MJ, Hsu KC, Lin TE, Chuang JY, Liou JP.
    Eur J Med Chem; 2021 May 05; 217():113338. PubMed ID: 33744690
    [Abstract] [Full Text] [Related]

  • 20. Design and biological evaluation of tetrahydro-β-carboline derivatives as highly potent histone deacetylase 6 (HDAC6) inhibitors.
    Leonhardt M, Sellmer A, Krämer OH, Dove S, Elz S, Kraus B, Beyer M, Mahboobi S.
    Eur J Med Chem; 2018 May 25; 152():329-357. PubMed ID: 29738953
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.